3-year work plan for the joint CHMP/CVMP Quality Working Party 2026-2028
Submitted by Anonymous (not verified) on 9 December 2025 - 11:13
3-year work plan for the joint CHMP/CVMP Quality Working Party 2026-2028
Consolidated 3-year rolling work plan for the Non-clinical domain 2026-2028
Submitted by Anonymous (not verified) on 9 December 2025 - 11:06
Consolidated 3-year rolling work plan for the Non-clinical domain 2026-2028
Questions and answers for biological medicinal products
Submitted by Anonymous (not verified) on 9 December 2025 - 10:57
Questions and answers for biological medicinal products
New Approach Methodologies EU-IN Horizon Scanning Report
Submitted by Anonymous (not verified) on 9 December 2025 - 10:43
New Approach Methodologies EU-IN Horizon Scanning Report
3-year rolling work plan for the Biosimilar Medicinal Products Working Party 2026-2028
Submitted by Anonymous (not verified) on 9 December 2025 - 10:41
3-year rolling work plan for the Biosimilar Medicinal Products Working Party 2026-2028
Alzheimer’s disease EU-IN Horizon Scanning Report
Submitted by Anonymous (not verified) on 9 December 2025 - 10:41
Alzheimer’s disease EU-IN Horizon Scanning Report
3-year work plan for the Biologics Working Party (BWP) 2026-2028
Submitted by Anonymous (not verified) on 9 December 2025 - 10:36
3-year work plan for the Biologics Working Party (BWP) 2026-2028
Human medicines European public assessment report (EPAR): Aubagio, teriflunomide, Date of authorisation: 26/08/2013, Revision: 30, Status: Authorised
Submitted by Anonymous (not verified) on 9 December 2025 - 10:35
Human medicines European public assessment report (EPAR): Aubagio, teriflunomide, Date of authorisation: 26/08/2013, Revision: 30, Status: Authorised
Guideline on the development and manufacture of synthetic peptides
Submitted by Anonymous (not verified) on 9 December 2025 - 10:27
Guideline on the development and manufacture of synthetic peptides
Human medicines European public assessment report (EPAR): Eviplera, emtricitabine,rilpivirine,tenofovir disoproxil, Date of authorisation: 27/11/2011, Revision: 27, Status: Authorised
Submitted by Anonymous (not verified) on 9 December 2025 - 10:15
Human medicines European public assessment report (EPAR): Eviplera, emtricitabine,rilpivirine,tenofovir disoproxil, Date of authorisation: 27/11/2011, Revision: 27, Status: Authorised